Generics - Teva Pharmaceutical Industries, Anti-virals

Filter

Popular Filters

Mixed US court decision on ViiV Healthcare’s Epzicom and Trizivir patents

19-12-2013

UK pharma giant GlaxoSmithKline and ViiV Healthcare confirmed that the US District Court for the District…

Anti-viralsEpzicomGenericsGlaxoSmithKlineLegalLupinPatentsTeva Pharmaceutical IndustriesTrizivirViiV Healthcare

Gilead and Teva settle Viread patent litigation

20-02-2013

US biotech firm Gilead Sciences (Nasdaq: GILD), a global leader in the HIV/AIDS drug market, has reached…

Anti-viralsBiotechnologyGenericsGilead SciencesNorth AmericaPatentsTeva Pharmaceutical IndustriesViread

Bristol-Myers gets $438 million under Latin America OTC deal with Reckitt Benckiser; Baraclude patent ruled invalid

13-02-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) has entered into a three-year collaboration agreement…

Anti-viralsBaracludeBristol-Myers SquibbGenericsLicensingNorth AmericaPatentsPharmaceuticalReckitt BenckiserSouth AmericaTeva Pharmaceutical Industries

FDA delays once-a-day Prezista approval; finds counterfeit of Teva's Adderall

30-05-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Therapeutics division has received a complete…

AdderallAnti-viralsGenericsJanssenJohnson & JohnsonMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalPrezistaRegulationTeva Pharmaceutical Industries

Company Spotlight

ImmunoGen

ImmunoGen

Back to top